Charles de Chasteigner du Mée
Private Equity Investor bij Accelerated Venture Partners LLC
Profiel
Charles P.
R.
de Chasteigner du Mée is the founder of Nascent Pharmaceuticals, Inc. (founded in 1999) and Redwood Pharma AB (founded in 2012).
At Nascent Pharmaceuticals, he held the title of Director & Vice President-Development.
At Redwood Pharma AB, he held the title of Director & Chief Development Officer from 2012 to 2017.
Currently, Dr. de Chasteigner du Mée is a Partner at Accelerated Venture Partners LLC, a position he has held since 2008.
In the past, he worked as Vice President at COR Therapeutics, Inc. from 1990 to 1998, as Principal at Genentech, Inc. in 1989, and as Principal at Monsanto Co. from 1983 to 1984.
Dr. de Chasteigner du Mée received his undergraduate degree from the University of Natal, his doctorate from the University of Florida in 1984, and his MBA from the University of San Francisco in 2009.
Actieve functies van Charles de Chasteigner du Mée
| Bedrijven | Functie | Begin |
|---|---|---|
Accelerated Venture Partners LLC
 Accelerated Venture Partners LLC Investment ManagersFinance Accelerated Venture Partners LLC (Accelerated Venture Partners) is a private equity firm founded in 2008. The firm is headquartered in San Mateo, California. | Private Equity Investor | 01-01-2008 |
Eerdere bekende functies van Charles de Chasteigner du Mée
| Bedrijven | Functie | Einde |
|---|---|---|
| REDWOOD PHARMA AB | Oprichter | 02-01-2017 |
Nascent Pharmaceuticals, Inc.
 Nascent Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Nascent Pharmaceuticals, Inc. manufactured pharmaceuticals and drugs. The company was founded by Charles P. R. de C. du Mée and Gene Barnett in 1999 and was headquartered in Durham, NC. | Oprichter | 31-01-2008 |
COR Therapeutics, Inc.
 COR Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology COR Therapeutics, Inc.. The principal activities of the Company are the discovery, development and commercialization of novel pharmaceutical products to establish new standards of care for the treatment and prevention of severe cardiovascular diseases. Integrilin was the Company's first product taken from discovery to commercialization. A drug was approved to treat patients who undergo a procedure known as angioplasty to open blood vessels. This drug has also been approved to treat patients with intermittent chest pains known as unstable angina and patients suffering from a kind of Heart attack known as non-Q-wave myocardial infraction | Corporate Officer/Principal | - |
Genentech, Inc.
 Genentech, Inc. BiotechnologyHealth Technology Genentech, Inc. develops, manufactures and markets pharmaceutical products for life-threatening medical conditions. It studies various areas including oncology, immunology, neuroscience, ophthalmic diseases, microbial pathogenesis, metabolic diseases, cardiovascular diseases, and opportunistic areas. The company was founded by Herb W. Boyer and Robert A. Swanson in 1976 and is headquartered in South San Francisco, CA. | Corporate Officer/Principal | 31-12-1989 |
| MONSANTO | Corporate Officer/Principal | - |
Opleiding van Charles de Chasteigner du Mée
| University of Florida | Doctorate Degree |
| University of San Francisco | Masters Business Admin |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Beursgenoteerde bedrijven | 1 |
|---|---|
| REDWOOD PHARMA AB | Health Technology |
| Bedrijven in privébezit | 6 |
|---|---|
COR Therapeutics, Inc.
COR Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology COR Therapeutics, Inc.. The principal activities of the Company are the discovery, development and commercialization of novel pharmaceutical products to establish new standards of care for the treatment and prevention of severe cardiovascular diseases. Integrilin was the Company's first product taken from discovery to commercialization. A drug was approved to treat patients who undergo a procedure known as angioplasty to open blood vessels. This drug has also been approved to treat patients with intermittent chest pains known as unstable angina and patients suffering from a kind of Heart attack known as non-Q-wave myocardial infraction | Health Technology |
Genentech, Inc.
Genentech, Inc. BiotechnologyHealth Technology Genentech, Inc. develops, manufactures and markets pharmaceutical products for life-threatening medical conditions. It studies various areas including oncology, immunology, neuroscience, ophthalmic diseases, microbial pathogenesis, metabolic diseases, cardiovascular diseases, and opportunistic areas. The company was founded by Herb W. Boyer and Robert A. Swanson in 1976 and is headquartered in South San Francisco, CA. | Health Technology |
Monsanto Co.
 Monsanto Co. Wholesale DistributorsDistribution Services Monsanto Co. engages in the provision of agricultural products to farmers. It provides other seed companies with genetic material and biotechnology traits for their seed brands. The company was founded by John F. Queeny in 1901 and is headquartered in St. Louis, MO. | Distribution Services |
Accelerated Venture Partners LLC
Accelerated Venture Partners LLC Investment ManagersFinance Accelerated Venture Partners LLC (Accelerated Venture Partners) is a private equity firm founded in 2008. The firm is headquartered in San Mateo, California. | Finance |
| University of Natal | Consumer Services |
Nascent Pharmaceuticals, Inc.
Nascent Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Nascent Pharmaceuticals, Inc. manufactured pharmaceuticals and drugs. The company was founded by Charles P. R. de C. du Mée and Gene Barnett in 1999 and was headquartered in Durham, NC. | Health Technology |
